tiprankstipranks

Peter Palframan Insider Profile

4 Followers
Peter Palframan, Director at Cynapsus Therapeutics, holds 439.00K shares in Zoomermedia (Ticker: ZUMRF), holds 70.00K shares in Cynapsus Therapeutics (Ticker: CYNA). Most recently, Peter Palframan Sold ― shares of Zoomermedia on May 15, 2021 for an estimated value of 2.63K.
tipranks
Peter  Palframan

Peter Palframan
Cynapsus Therapeutics (CYNA)
Director

Ranked #34,580 out of 97,997 Corporate Insiders

Profitable Transactions

100%
2 out of 2 Profitable Transactions

Average Return

+30.60%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$220K
100.00%
A breakdown of Peter Palframan's holdings

Insider Roles

Zoomermedia
(ZUMRF)
Director
Roles that Peter Palframan holds in companies

Most Profitable Insider Trade

Stock:
Zoomermedia
(ZUMRF)
Rating:Informative Sell
Date:May 10, 2021 - May 10, 2022
Return:+30.60%
The most profitable trade made by Peter Palframan

Peter Palframan's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
CYNA
Cynapsus Therapeutics
Mar 05, 2009
Informative Buy
7.00K
$2.83M
Zoomermedia
May 15, 2021
Director
Informative Sell
2.63K
$220.38K
List of latest transactions for each holding click on a transaction to see Peter Palframan's performance on stock

Peter Palframan insider profile FAQ

What is the percentage of profitable transactions made by Peter Palframan?
The percentage of profitable transactions made by Peter Palframan is 100%.
    What is the average return per transaction made by Peter Palframan?
    The average return per transaction made by Peter Palframan is 30.60%.
      What stocks does Peter Palframan hold?
      Peter Palframan holds: CYNA, ZUMRF stocks.
        What was Peter Palframan’s latest transaction?
        Peter Palframan latest transaction was an Informative Sell of $2.63K.
          What was Peter Palframan's most profitable transaction?
          Peter Palframan’s most profitable transaction was an Informative Sell of ZUMRF stock on May 10, 2021. The return on the trade was 30.60%.
            What is Peter Palframan's role in Cynapsus Therapeutics?
            Peter Palframan's role in Cynapsus Therapeutics is Director.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.